Skip to main content

Table 5 Weibull survival model with random effects in 2131 children on antiretroviral therapy (ART).

From: 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008

  Univariate analysis Multivariate analysis
  HR* CI (95%)** P aHR CI (95%)** P
Sex       
   Boys 1 - - 1 - -
   Girls 1.0 0.8-1.3 0.72 1.0 0.8-1.2 0.78
Age at ART initiation       
   10 years and plus 1 - - 1 - -
   [5-10] years 0.9 0.6-1.2 0.32 0.9 0.7-1.3 0.56
   [3-5] years 0.8 0.5-1.2 0.22 0.9 0.6-1.3 0.52
   [1-3] years 1.3 0.9-1.8 0.10 1.1 0.8-1.6 0.34
   < 12 months 1.4 0.6-2.9 0.36 1.1 0.5-2.4 0.66
ART regimen at baseline       
   2 NRTI+1 NNRTI 1 - - 1   
   2 NRTI+1 IP 0.7 0.5-0.9 0.01 0.9 0.7-1.2 0.62
   Other 0.6 0.2-1.5 0.24 1.0 0.4-2.5 0.98
Clinical stage at ART initiation       
   A, B or I, II, III 1 - - 1 - -
   AIDS or IV 2.6 2.0-3.5 < 0.01 2.3 1.7-3.0 < 0.01
   Unknown 1.3 0.8-2.1 0.21 1.4 0.9-2.3 0.15
% CD4 at ART initiation       
   ≥ 15% 1 - - 1 - -
   < 15% 2.1 1.4.3.2 < 0.01 1.9 1.3-2.9 < 0.01
   Missing 1.5 0.9-2.5 0.07 1.7 1.1-2.8 0.03
Year of ART initiation       
   ≤ 2004 1 - - 1 - -
   2005 2.0 1.5-2.7 < 0.01 1.7 1.3-2.4 < 0.01
   ≥ 2006 3.5 2.6-4.6 < 0.01 3.0 2.2-4.0 < 0.01
Cotrimoxazole status at ART initiation       
   No 1 - - 1 - -
   Yes 1.2 0.7-1.8 0.43 0.9 0.6-1.4 0.63
   Missing 0.6 0.2-1.8 0.32 0.4 0.1-1.5 0.16
  1. IeDEA paediatric West Africa database (pWADA), 2000-2007. Loss-to-program analysis.
  2. *HR = Hazard Ratio, **95% CI = 95% Confidence Interval, aHR = adjusted Hazard Ratio
  3. Heterogeneity between cohort, p = 0.14